Every S-1 that Jaguar Health, Inc. (JAGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow JAGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAGX filings page.
Jaguar Health, Inc. is registering 41,000,000 shares of common stock for potential resale by C/M Capital Master Fund, LP under a committed equity financing structure. This consists of up to 40,000,000 Purchase Shares issuable under a June 9, 2026 common stock purchase agreement plus up to 1,000,000 Commitment Shares issued as consideration.
The company will not receive proceeds from resale of these shares, but may raise up to $40 million in gross proceeds from selling shares to C/M Capital over time, subject to pricing formulas, an $1.10 floor price, ownership caps and other conditions. Shares outstanding were 4,910,402 as of July 10, 2026; issuing all 41,000,000 registered shares would represent over 89.3% of that total, creating significant potential dilution.
Jaguar develops crofelemer-based therapies for complex gastrointestinal and intestinal failure conditions, with FDA-approved Mytesi and multiple orphan-designated programs. Recent financings include a $2.0 million private placement of Series P preferred stock and a fully converted Series O preferred stock dividend, both adding to the capital structure described in this prospectus.
Jaguar Health, Inc. is registering for resale up to 40,800,000 shares of common stock held or issuable to C/M Capital Master Fund, LP under a committed equity line. Jaguar is not selling shares in this prospectus and will receive no proceeds from the selling stockholder’s resales.
Under a June 2026 purchase agreement, Jaguar may sell up to $40 million of stock to C/M Capital at its discretion, subject to a floor price of $1.10, daily caps and a 4.99% beneficial ownership limit. As of July 10 2026, Jaguar had 4,910,402 common shares outstanding; if all 40,800,000 registered shares were issued, they would exceed 89.3% of then-outstanding shares, implying substantial potential dilution.
Recent financings include a January 2026 US license with Future Pak providing $16.0 million upfront plus potential $2.0 million additional and up to $20 million in milestones, a $2.0 million Series P preferred stock private placement, and conversion of Series O preferred into common stock. Jaguar’s lead drug crofelemer has FDA approval for HIV-related diarrhea and holds multiple orphan drug designations, with advanced development in rare intestinal failure disorders MVID and SBS-IF.
Jaguar Health has filed a resale registration covering up to 5,522,551 shares of common stock, all to be sold from time to time by selling stockholders under prior financing arrangements. The company is not selling shares in this offering and will not receive proceeds from these resales.
The registered shares are tied mainly to its June 2026 financing of 240 shares of Series P Preferred Stock for $2 million, including potential redemption, warrant and dividend shares linked to an 8% annual dividend. As of July 10, 2026, common shares outstanding were 4,910,402; if all registered shares were issued, they would represent more than 52.93% of the outstanding common stock, indicating substantial potential dilution and overhang.
Jaguar also describes a committed $40 million equity line of credit and a pipeline centered on crofelemer for HIV-related diarrhea, cancer therapy-related diarrhea and ultra-rare intestinal failure conditions, where crofelemer carries multiple Orphan Drug Designations in the US and EU.